Background and objective: Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. This article analyzed the efficacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC.
Methods: We retrospectively analyzed the short-term efficacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed.
Results: Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). The overall response rate was 5.9%, and the disease control rate was 47.1%. The median progression-free survival was 4.4 months (95%CI: 4.05-7.46). The main grade 3/4 toxicity was hand-foot skin reaction.
Conclusion: Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.
背景与目的 晚期非小细胞肺癌是一种无法治愈的常见恶性肿瘤。对于多程治疗后复发的患者目前尚无标准的治疗方法。本文分析了苹果酸舒尼替尼单药治疗多次复发的晚期非小细胞肺癌的疗效及安全性。方法 回顾性分析我科2011年1月-2012年12月采用苹果酸舒尼替尼37.5 mg/d持续给药的方法治疗的17例多程治疗后复发的晚期非小细胞肺癌患者的近期疗效、毒副反应及无进展生存时间。结果 17例患者中部分缓解1例（5.9%），稳定7例（41.2%），疾病进展9例（52.9%），客观缓解率5.9%，疾病控制率47.1%，中位无进展生存为4.4个月（95%CI: 4.05-7.46）。全组患者治疗耐受良好，3级/4级不良反应仅表现为手足皮肤反应（5.9%），其余药物相关不良事件均为1/2级。结论 苹果酸舒尼替尼37.5 mg/d持续治疗多程治疗后复发的晚期非小细胞肺癌可取得较好的客观疗效，耐受良好。